Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LF601
- Development stage
- Preclinical
- Lead developer
- Lifex Biolabs
- Modality
- Small Molecules
01
Overview
LF601 is a small molecule drug candidate being developed by Lifex Biolabs for the treatment of neurodegenerative disorders, specifically Parkinson's disease and dementia with Lewy bodies. The drug is currently in the discovery/preclinical stage. Lifex Biolabs utilizes a fragment-based drug discovery approach known as SAR by NMR (Structure-Activity Relationship by Nuclear Magnetic Resonance) to identify and optimize its pipeline candidates. While the specific molecular target for LF601 has not been publicly disclosed, the company's focus is on developing targeted small molecule therapies for high-unmet-need conditions.
02
Targets
NR4A3 (Nuclear receptor subfamily 4 group A member 3)
Beyond the preview
Go deeper on LF601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LF601.